| Decreased expression of the GABAA receptor in fragile X syndrome C d'Hulst, N De Geest, SP Reeve, D Van Dam, PP De Deyn, BA Hassan, ... Brain research 1121 (1), 238-245, 2006 | 357 | 2006 |
| Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition D Van Dam, R d'Hooge, M Staufenbiel, C Van Ginneken, F Van Meir, ... European Journal of Neuroscience 17 (2), 388-396, 2003 | 339 | 2003 |
| Animal models in the drug discovery pipeline for Alzheimer's disease D Van Dam, PP De Deyn British journal of pharmacology 164 (4), 1285-1300, 2011 | 304 | 2011 |
| Drug discovery in dementia: the role of rodent models D Van Dam, PP De Deyn Nature reviews Drug discovery 5 (11), 956-970, 2006 | 284 | 2006 |
| Immune hyperreactivity of Aβ plaque-associated microglia in Alzheimer's disease Z Yin, D Raj, N Saiepour, D Van Dam, N Brouwer, IR Holtman, BJL Eggen, ... Neurobiology of aging 55, 115-122, 2017 | 232 | 2017 |
| Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's … E Hudry, D Van Dam, W Kulik, PP De Deyn, FS Stet, O Ahouansou, ... Molecular Therapy 18 (1), 44-53, 2010 | 209 | 2010 |
| Spatial learning, contextual fear conditioning and conditioned emotional response in Fmr1 knockout mice D Van Dam, R d'Hooge, E Hauben, E Reyniers, I Gantois, CE Bakker, ... Behavioural brain research 117 (1-2), 127-136, 2000 | 176 | 2000 |
| Increased white matter inflammation in aging-and Alzheimer’s disease brain D Raj, Z Yin, M Breur, J Doorduin, IR Holtman, M Olah, IJ Mantingh-Otter, ... Frontiers in molecular neuroscience 10, 206, 2017 | 161 | 2017 |
| PTZ-induced seizures in mice require a revised Racine scale J Van Erum, D Van Dam, PP De Deyn Epilepsy & Behavior 95, 51-55, 2019 | 157 | 2019 |
| Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model D Van Dam, D Abramowski, M Staufenbiel, PP De Deyn Psychopharmacology 180, 177-190, 2005 | 148 | 2005 |
| Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model I Heulens, C D’Hulst, D Van Dam, PP De Deyn, RF Kooy Behavioural brain research 229 (1), 244-249, 2012 | 144 | 2012 |
| Effect of Morris water maze diameter on visual-spatial learning in different mouse strains D Van Dam, G Lenders, PP De Deyn Neurobiology of learning and memory 85 (2), 164-172, 2006 | 137 | 2006 |
| Region-and age-specific changes in glutamate transport in the AβPP23 mouse model for Alzheimer's disease A Schallier, I Smolders, D Van Dam, E Loyens, PP De Deyn, A Michotte, ... Journal of Alzheimer's Disease 24 (2), 287-300, 2011 | 132 | 2011 |
| Cellular ageing, increased mortality and FTLD‐TDP‐associated neuropathology in progranulin knockout mice H Wils, G Kleinberger, S Pereson, J Janssens, A Capell, D Van Dam, ... The Journal of pathology 228 (1), 67-76, 2012 | 131 | 2012 |
| Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS) D Van Dam, V Errijgers, RF Kooy, R Willemsen, E Mientjes, BA Oostra, ... Behavioural brain research 162 (2), 233-239, 2005 | 126 | 2005 |
| A new glaucoma hypothesis: a role of glymphatic system dysfunction P Wostyn, D Van Dam, K Audenaert, HE Killer, PP De Deyn, V De Groot Fluids and Barriers of the CNS 12, 1-6, 2015 | 111 | 2015 |
| Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy C Sevin, A Benraiss, D Van Dam, D Bonnin, G Nagels, L Verot, ... Human Molecular Genetics 15 (1), 53-64, 2006 | 107 | 2006 |
| Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease? AD Dekker, A Strydom, AMW Coppus, D Nizetic, Y Vermeiren, ... Cortex 73, 36-61, 2015 | 95 | 2015 |
| Sleep and Alzheimer's disease: a pivotal role for the suprachiasmatic nucleus J Van Erum, D Van Dam, PP De Deyn Sleep medicine reviews 40, 17-27, 2018 | 94 | 2018 |
| Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model D Van Dam, PP De Deyn European neuropsychopharmacology 16 (1), 59-69, 2006 | 93 | 2006 |
